17,261 trials
Untreated Adult Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose of Midostaurin in Combination With Azacitidine in Patients With Acute Myelogenous Leukemia (Phase I) — 75 mg/bid
Binge Eating Disorder
Primary: Change in Number of Binge Eating Episodes — .93; .76 binge eating episodes
Fatigue · Musculoskeletal Pain · Cognitive Decline
Primary: Physical Component of the SF-36 — 2.04; 2.55; 1.23; 4.45 score on a scale
Myalgic Encephalomyelitis · Chronic Fatigue Syndrome
Primary: Total Daily Symptom Score (TDSS) — 29.5; 28.7; 29.2; 31.3 units on a scale — p=0.011
Neoplasms
Primary: Number of Pariticipants With Adverse Events as a Measure of Safety and Tolerability — 4; 2 Count of Participants
Primary Myelofibrosis · Post-Polycythemia Vera-Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
Primary: Percentage of Participants With at Least 50% Reduction in Spleen Length From Baseline at Week 24 — 56.0 percentage of participants
Cancer Survivor · Prevention of Human Papillomavirus Infection
Primary: Prevalence of HPV Vaccine Initiation in Cancer Survivors (Aim 1 [Survey]) — 179 Participants
Systemic Sclerosis · Pulmonary Hypertension
Primary: Mean Pulmonary Arterial Pressure Change From Baseline — -1.0; -0.73 mmHg
Opioid Use Disorder · Chronic Pain
Primary: AUCss(Area Under the Plasma Concentration-time Curve During a 7-day Dosing Interval at Steady State) for Each Injection Site, i.e., Buttock (Reference), Abdomen, Thigh…
Breast Cancer
Primary: The Number of Evaluable Patients With Complete Response or Partial Response or Stable Disease for ≥10 Weeks From the First Infusion (6 Weeks After the Second Infusion)…
Alzheimer's Disease · Dementia With Lewy Bodies · Parkinson's Disease Dementia
Primary: Change From Baseline in Gait Speed (cm/Sec) Measurements From Baseline to the End of Each Double-blind Treatment Period Based on Computerized Gait Assessment Tools…
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Determined by Investigator — 17.1…
Multiple Myeloma
Primary: Overall Response Rate (ORR) by Independent Review Committee (IRC) (Full Analysis Population) — 31; 34; 48 Percentage of Participants
Chronic Diarrhea · Irritable Bowel Syndrome With Diarrhea · Bile Acid Malabsorption
Primary: Total Fecal Bile Acid (BA) Excretion — 10.7; 3.6 μmoles/g — p=0.001
Feeding; Difficult, Newborn · Growth Failure · Necrotizing Enterocolitis
Primary: Time to Establish Full Enteral Feeds — 15; 15 days